Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

Obesity Clinical Trial

— PE  

Official title:

The Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health in Metabolically Abnormal Obese Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02706288
• Other study ID #: 201512088
• Status: Completed
• Phase: N/A
• Start date: March 2016
• Est. completion date: December 2022

Study information

• Verified date: December 2022
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to understand how weight loss by a very low fat plant-based diet with an exercise program affects metabolic and cardiovascular health in overweight adults at high risk for disease. Outcome measures will include assessment of insulin sensitivity, β-cell function, body fat distribution, skeletal muscle and adipose tissue biology, cardiovascular function, cardiorespiratory fitness, muscular strength, immune function, and the gut microbiome.

Description:

Reduced energy intake and increased physical activity have profound effects on cardiometabolic health as assessed by insulin sensitivity, β-cell function, serum lipids, intra-abdominal fat mass, intrahepatic triglyceride content, and blood pressure, and is the cornerstone of treatment for people with obesity. However, the specific additional therapeutic effects of regular exercise in conjunction with diet-induced weight loss are not clear. In addition, the optimal dietary macronutrient composition needed to reduce cardiometabolic risk is not known. The use of a very low fat, plant-forward diet is becoming increasingly popular to treat people with obesity and is the only diet therapy that is reimbursed by Medicare in the treatment of people with coronary heart disease.

Participants will undergo nutritional counseling and have supervised exercise training 4 days per week plus unsupervised exercise sessions performed 2 days per week until 7-10% weight loss is achieved. Meals will be provided and food diaries will be kept during weight loss. Tests before and after the intervention will include muscular strength and aerobic fitness, cardiovascular assessments, glucose tolerance tests, hyperinsulinemic euglycemic clamp test for insulin sensitivity, muscle biopsies, body composition scans, blood tests, and urine and stool collections.

The overarching goal of this project is to conduct a comprehensive characterization of weight loss induced by using a PB diet with regular exercise in people with obesity, prediabetes and insulin resistance, followed by a comparison of the effects of this study with those from another study that is evaluating the effect of the same amount of weight loss induced by using a PB diet alone, without exercise. Specifically, we will evaluate changes in body composition, body fat distribution, cardiopulmonary function, muscle strength, the plasma proteome, insulin sensitivity, beta-cell function, systemic inflammation, muscle cellular metabolic pathways, and the gut microbiome to determine cellular, multiorgan, and whole-body effects of PB diet alone and PB diet plus exercise. Accordingly, this study will fill two important gaps in our knowledge that have considerable physiological and clinical significance; the data from this study will provide: 1) a better understanding of the effects of calorie restriction-induced weight loss plus exercise on a series of key outcome measures, and 2) the potential additional benefit of adding regular exercise to a plant-forward diet.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: December 2022
• Est. primary completion date: December 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Age =18 and =55 years

• BMI =30.0 and =50.0 kg/m²

• HbA1c =5.7%, or fasting plasma glucose concentration =100 mg/dl, or 2-hr OGTT plasma glucose concentration =140 mg/dl

Exclusion Criteria:

• Medical, surgical, or biological menopause

• Previous bariatric surgery

• Structured exercise >2 days/week for =35 minutes of intense exercise (e.g., jogging, activity that causes heavy breathing and sweating) or =150 min per week of structured exercise (e.g., brisk walking)

• Unstable weight (>4% change during the last 2 months before entering the study)

• Significant organ system dysfunction (e.g., diabetes requiring medications, severe pulmonary, kidney or cardiovascular disease)

• Cancer or cancer that has been in remission for <5 years

• Polycystic ovary syndrome

• Major psychiatric illness

• Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)

• Use of medications that are known to affect the study outcome measures (e.g., steroids, non-statin lipid lowering medications) or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study

• Use of antibiotics in last 60 days

• Smoke cigarettes, use marijuana >2 x/week, or use of illegal drugs

• Men who consume >21 units (e.g. glass of wine or bottle of beer) of alcohol per week and women who consume >14 units of alcohol per week

• Pregnant or lactating women

• Vegans, vegetarians, those with lactose intolerance and/or severe aversions/sensitivities to eggs, fish, nuts, wheat and soy, and/or any individuals with food allergies that induce an anaphylactic response

• Persons who are not able to grant voluntary informed consent

• Persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers not an appropriate candidate for this study, including non-compliance with screening appointments or study visits

Related Conditions & MeSH terms

• Insulin Resistance
• Obesity

Intervention

Other:
• Weight loss with very low fat plant-based diet and regular exercise
Participants will lose ~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)

Locations

Country	Name	City	State
United States	Washington University in St. Louis School of Medicine	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	The Foundation for Barnes-Jewish Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in insulin sensitivity	Liver and skeletal muscle insulin sensitivity will be assessed by hyperinsulinemic euglycemic clamp technique, before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in aerobic fitness	Maximal oxygen consumption will be assessed using indirect calorimetry during a graded exercise test to volitional fatigue, before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in muscular strength	Muscle strength will be evaluated as the maximal amount of weight the participant is able to lift for one repetition (1 RM) for the following exercises: leg press, seated row, knee flexion, and chest press, before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in fat mass and fat free mass	Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA) before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in intra-hepatic triglyceride content	Intra-hepatic triglyceride content will be assessed by magnetic resonance imaging (MRI) before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in fasting plasma glucose	Fasting plasma glucose concentrations will be evaluated from a fasting blood sample before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in glycosylated hemoglobin (HbA1c)	HbA1c will be evaluated from a fasting blood sample before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in 24 hour glucose concentrations with feeding	Glucose concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in 24 hour metabolite concentrations with feeding	Metabolite concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in 24 hour hormone concentrations with feeding	Hormone concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in markers of inflammation	Markers of inflammation will be evaluated from blood samples collected before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in plasma proteome	Plasma proteome will be evaluated from blood samples collected before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Changes in gene expression in skeletal muscle tissue	Gene expression in thigh muscle tissue will be evaluated before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Changes in body weight	Body weight will be measured before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Changes in body mass index	Body mass index will be calculated from weight and height before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in exosome-mediated intercellular signaling	Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in gut microbiome	Gut microbiota, meta-transcriptome (bacterial RNA sequencing to determine what proteins can be made by the microbiota) and the meta-metabolome (metabolites made by the microbiota) will be assessed before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in beta-cell function	Beta-cell function will be assessed from a modified oral glucose tolerance test before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss
Secondary	Change in insulin clearance	Beta-cell function will be assessed from a modified oral glucose tolerance test and during the 24-hour study performed before and after weight loss.	An average of 4 months from baseline testing to 7-10% weight loss